The European Mediscience Awards is the largest annual gathering of private and publicly-quoted healthcare, biotech and life sciences companies in Europe. The awards celebrate the best breakthroughs, technology and significant contributions from individuals and companies in the Mediscience sector.
Jonathan’s commitment to the Mediscience sector, is driven by a passion for a better understanding of human health and disease. Starting out as a breast cancer researcher at the University of Cambridge, and frustrated by a lack of high-quality antibodies in the marketplace, Jonathan founded Abcam in 1998. Dubbed the ‘Amazon of Antibodies’ for its unique data-rich products, the Company has evolved from humble beginnings and is now a market leader providing innovative products such as RabMAb® primaries and a range of other life science products to help advance protein research globally.
In recent years, Jonathan has been involved with several exciting research initiatives and is the co-founder and principle investor in Horizon Discovery and Axol Bioscience.
Dr Jonathan Milner, CEO, Abcam, said: “I’m delighted to have won the award for the most significant contribution to the Mediscience sector. At Abcam, we’re passionate about accelerating the pace of scientific discoveries to better understand human health and disease. I would like to thank our employees who are dedicated to our mission of enabling scientists to discover more.”
About Abcam
Abcam plc is a leading provider of innovative protein research tools and services, with an unrivalled range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company’s catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.
Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices enabling local services, multi-language support and next-day delivery in over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange. (AIM: ABC).
To find out more, please visit www.abcam.com
*******
Contacts:
Abcam
Francesca Axe
T: +44 (0) 1223 696000
Media enquiries
Katie Odgaard / Lorna Cuddon
Zyme Communications
E: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
T: +44 (0) 7787 502 947 / +44 (0)7811 996 942
_________________________________________________